LONSURF® (trifluridine and tipiracil) tablets | Previously Treated mCRC Treatment | TAS-102 Efficacy
Colorectal cancer drugs market | Nature Reviews Drug Discovery
Lonsurf® Treatment for Colorectal Cancer - CancerConnect
Adding Avastin to Lonsurf Improved Outcomes in Pretreated Colorectal Cancer
Trifluridine/Tipiracil Combination Misses Mark in Metastatic Colon Cancer | MedPage Today
LONSURF® (trifluridine and tipiracil) tablets | Previously Treated mCRC Treatment | TAS-102 Efficacy
Current Oncology | Free Full-Text | A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series
How to Take LONSURF® (trifluridine and tipiracil) tablets | Helpful Dosage Reminders
NCCN® Guidelines for Metastatic Colon Cancer Treatment
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer
How does chemo fit into my treatment plan? - Colontown University
Avastin® (bevacizumab) Dosing | MCRC Treatment
PDF) Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
These highlights do not include all the information needed to use LONSURF safely and effectively. See full prescribing information for LONSURF. LONSURF (trifluridine and tipiracil) tablets, for oral use Initial U.S. Approval:
La FDA approuve Lonsurf plus bevacizumab pour le traitement du cancer colorectal métastatique - Colorectal Cancer Canada
Servier et Taiho Oncology présentent des données sur la survie globale de trifluridine/tipiracil (LONSURF®) en association avec le bevacizumab chez des patients atteints d'un cancer colorectal métastatique réfractaire... | Business Wire
Lonsurf Plus Bevacizumab Approved for Metastatic Colorectal Cancer
NEJM on X: "Among patients with metastatic colorectal cancer, treatment with trifluridine–tipiracil plus bevacizumab as third-line therapy resulted in longer overall survival than trifluridine–tipiracil alone (SUNLIGHT trial). https://t.co/C4DZvyiZiD ...
Servier, Taiho score phase 3 colorectal cancer win to support Lonsurf combo nod
Taiho Oncology et Servier annoncent la publication dans le New England Journal of Medicine des données de l'étude pivot de phase 3 sur l'association trifluridine/tipiracil (LONSURF®) plus bévacizumab chez le patients atteint
Avastin and Lonsurf for Advanced Colorectal Cancer - NCI
Benefits & Risks of Treatment | Metastatic Colorectal Cancer (mCRC)| Avastin® (bevacizumab)
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer
Servier et Taiho Oncology présentent des données sur la survie globale de trifluridine/tipiracil (LONSURF®) en association avec le bevacizumab chez des patients atteints d'un cancer colorectal métastatique réfractaire... | Business Wire
